Literature DB >> 1916662

Bone loss after liver transplantation.

J A McDonald1, C R Dunstan, P Dilworth, K Sherbon, A G Sheil, R A Evans, G W McCaughan.   

Abstract

We studied 35 adult patients (mean age = 43 yr) referred for orthotopic liver transplantation. Spinal bone mineral density was measured by quantitative computed tomography scanning before transplantation (n = 35) and at 3 mo (n = 21) and 12 mo (n = 11) after orthotopic liver transplantation. The readings were corrected to age 50 yr, using the regression equations derived from normal control subjects. Quantitative bone histological studies were performed in 17 patients before orthotopic liver transplantation and 3 mo after orthotopic liver transplantation. Before orthotopic liver transplantation, the corrected spinal bone mineral density in men was 108 +/- 20 mg/cm3, less than in male control subjects (129 +/- 22 mg/cm3, p less than 0.005). In women patients the value was 117 +/- 27 mg/cm3, and in female control subjects 126 +/- 19 mg/cm3 (NS). However, women patients with primary biliary cirrhosis had lower spinal bone mineral density (106.5 +/- 14.8) than female control subjects (p less than 0.005). Histologically, the resorbing surface was near the normal mean, whereas the osteoblast surface, tetracycline surface and bone formation rate was lower in men (p less than 0.05) but not women. Spinal bone mineral density decreased by 24% in the first 3 mo after orthotopic liver transplantation with no further decrease at 12 mo. Five patients had vertebral fractures within 6 mo of orthotopic liver transplantation. One patient fractured a wrist and three had osteonecrosis of the hip or knee.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1916662     DOI: 10.1016/0270-9139(91)90047-y

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

2.  Comments on "cyclosporin does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat".

Authors:  S Epstein; W S Jee; Y Ma; C C Liu
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

Review 3.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

Review 4.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

5.  Hepatic osteodystrophy is common in patients with noncholestatic liver disease.

Authors:  N S Choudhary; M Tomar; Y K Chawla; S K Bhadada; N Khandelwal; R K Dhiman; A Duseja; A Bhansali
Journal:  Dig Dis Sci       Date:  2011-05-15       Impact factor: 3.199

6.  Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen.

Authors:  S C Riemens; A Oostdijk; J J van Doormaal; C J Thijn; G Drent; D A Piers; E W Groen; L Meerman; M J Slooff; E B Haagsma
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

7.  Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation.

Authors:  Rinkesh Kumar Bansal; Mandhir Kumar; Piyush Ranjan Munish Sachdeva; Ashish Kumar
Journal:  United European Gastroenterol J       Date:  2015-05-05       Impact factor: 4.623

Review 8.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

9.  The heterogeneity of bone disease in cirrhosis: a multivariate analysis.

Authors:  Bronwyn A L Crawford; C Kam; A J Donaghy; G W McCaughan
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

10.  Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.

Authors:  Hyeonju Yeo; Lauren H Beck; Jay M McDonald; Majd Zayzafoon
Journal:  Bone       Date:  2007-02-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.